-
Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
-
AAPM&R Delegates Successfully Advocate for New Policy at AMA House of Delegates Meeting
-
15 Days Left to Submit an Informal Review Request - Review Your 2016 PQRS Feedback Report and 2016 Annual Quality and Resource Use Report Now
-
Update on Therapy Caps Legislation
-
Congratulations to Our 25-Year Members
-
Academy Endorses AMA Opioid Task Force Naloxone One-Pager
-
Compounded Glutamine, Arginine, and Carnitine Product for Injection by United Pharmacy: Compounding Risk Alert - FDA Investigates Two Adverse Events
-
Registry Participant Spotlight: Texas Pain Treatment Center
-
2017 AAPM&R Annual Business Meeting
-
Congratulations to the 2017 PM&R Journal Best Paper Award Recipients
-
CMS Finalizes Policies that Reduce Provider Burden, Lower Drug Prices
-
Experts Needed for Instructional Videos
-
Fresenius Kabi Issues Voluntary Nationwide Recall of Midazolam Injection, USP, 2 mg/2 mL Due to Reports of Blister Packages Containing Syringes of Ondansetron Injection, USP, 4 mg/2 mL
-
Physio-Control Launches Voluntary Field Action for Specific Production Lots of Infant/Child Reduced Energy Defibrillation Electrodes Produced by Cardinal Health
-
Ridge Properties DBA Pain Relief Naturally Issues Voluntary Nationwide Recall of all lots of Naturally HL Bedsore Cream, Pretat by TAT Balm Carbomer Free Gel, & All Naturally HL Hemorrhoid products due to manufacturing concerns at the facility
-
CMS Finalizes Quality Payment Program Rule for Year 2 to Increase Flexibility and Reduce Burdens
-
Renew Your 2018 AAPM&R Membership
-
2018 Call for Proposals and Abstracts is Open
-
Dr. Andrew Friedman Appointed to NQP Opioid Stewardship Action Team
-
National Quality Forum (NQF) Seeking Patients to Serve on Cancer Standing Committee